BamSEC and AlphaSense Join Forces
Learn More

Aardvark Therapeutics Inc. – Material Contracts

NASDAQ: AARD    
Share price (6/1/26): $3.99    
Market cap (6/1/26): $87.0 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 6 pages February 9, 2026 Bryan Jones […***…] […***…] via Email: […***…] 1
12/34/56
EX-10.3
from 10-Q 7 pages Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.1
from 10-Q 17 pages Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan
12/34/56
EX-10.5
from S-8 13 pages Aardvark Therapeutics, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: December 18, 2024 Approved by the Stockholders: February 5, 2025 Ipo Date: February 12, 2025
12/34/56
EX-10.2
from S-8 26 pages Aardvark Therapeutics, Inc. 2025 Equity Incentive Plan Adopted by the Board of Directors: December 18, 2024 Approved by the Stockholders: February 5, 2025 Ipo Date: February 12, 2025
12/34/56
EX-10.5
from S-1/A 12 pages Aardvark Therapeutics, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: December 18, 2024 Approved by the Stockholders: February 5, 2025 Ipo Date: [ ], 2025
12/34/56
EX-10.4
from S-1/A 5 pages Aardvark Therapeutics, Inc. Rsu Award Grant Notice
12/34/56
EX-10.3
from S-1/A 6 pages Aardvark Therapeutics, Inc. Stock Option Grant Notice
12/34/56
EX-10.2
from S-1/A 22 pages Aardvark Therapeutics, Inc. 2025 Equity Incentive Plan Adopted by the Board of Directors: December 18, 2024 Approved by the Stockholders: February 5, 2025 Ipo Date: [ ], 2025
12/34/56
EX-10.13
from S-1 13 pages Aardvark Therapeutics, Inc. Severance Plan and Summary Plan Description
12/34/56
EX-10.12
from S-1 4 pages Aardvark Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.11
from S-1 74 pages Aardvark Therapeutics, Inc. Amended and Restated Investors’ Rights Agreement May 1, 2024
12/34/56
EX-10.10
from S-1 6 pages August 23, 2024 Manasi Sinha Jaiman […***…] […***…] […***…] Re: Offer of Employment Dear Manasi
12/34/56
EX-10.9
from S-1 4 pages August 23, 2021 Nelson Sun […***…] […***…] Re: Offer of Employment Dear Nelson: Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) Is Pleased to Offer You the Full-Time Exempt Position of Chief Financial Officer on the Following Terms
12/34/56
EX-10.8
from S-1 4 pages September 29, 2021 Bryan Jones […***…] […***…] Re: Offer of Employment Dear Bryan: Aardvark Therapeutics, Inc. (“Aardvark.” or the “Company”) Is Pleased to Offer You the Full-Time Exempt Position of Chief Business Officer on the Following Terms Beginning on October 4, 2021
12/34/56
EX-10.7
from S-1 5 pages July 24, 2019 Tien-LI Lee, M.D. […***…] […***…] Re: Offer of Employment Dear Tien: Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) Is Pleased to Offer You the Full-Time Exempt Position of Chief Executive Officer and President on the Following Terms
12/34/56
EX-10.6
from S-1 10 pages Indemnification Agreement
12/34/56
EX-10.1
from S-1 40 pages Aardvark Therapeutics, Inc. 2017 Equity Incentive Plan Adopted by the Board of Directors: May 26, 2017 Approved by the Stockholders: May 26, 2017 Effective Date: May 26, 2017 Termination Date: May 25, 2027
12/34/56
EX-10.14
from DRS/A 13 pages Aardvark Therapeutics, Inc. Severance Plan and Summary Plan Description
12/34/56